Abeona Therapeutics Inc.

ABEO Healthcare Biotechnology

Abeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023. In the quarter to June 2026, revenue grew 225.1%, EPS fell 116.9%, free cash flow grew 17.1% and total debt fell 23.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

4.43 0.22 −4.73%
Market cap
$265.9M
P/E
0.0×
Fwd P/E
−7.4×
Dividend yield
—
F-score
n/a
Altman Z
−2.32
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

75.90% 70.05% 70.99% (43.13%)
ROA
46.83% 43.34% 44.41% (29.54%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
40.31% 40.37% 40.70% (41.95%)
Average Days of Receivables
0.00 261.08 135.74 139.25
Free Cash Flow per Share
(1.52) (1.59) (1.51) (1.43)
Free Cash Flow
(82.36) (84.30) (85.24) (81.53)
Other line items

Show all line items

Columns are period end dates